Rare lephants
Screener

Gilead Sciences, Inc.

GILD ·Healthcare, Drug Manufacturers - General, United States
Analysis › KPI Dashboard

As of Fiscal Year 2025 (ended December 31, 2025)

Key KPIs at a Glance

Metric Value
Total revenue (FY2025) $29.44 billion, up 2% year-over-year
Total product sales (FY2025) $28.92 billion, up 1% year-over-year (up 4% excluding Veklury)
HIV franchise revenue (FY2025) $20.75 billion, up 6% year-over-year -- Biktarvy $14.33 billion (+7%), Descovy $2.76 billion (+31%)
GAAP net income (FY2025) $8.51 billion, GAAP diluted EPS of $6.78 (vs. $480 million and $0.38 in FY2024)
Non-GAAP net income (FY2025) $10.23 billion, non-GAAP diluted EPS of $8.15
R&D expense (FY2025) $5.80 billion, roughly flat vs. $5.91 billion in FY2024
GAAP operating income (FY2025) $10.02 billion, 34.0% GAAP operating margin
HIV treatment / PrEP market share Biktarvy holds more than 52% of the U.S. HIV treatment market; Descovy holds a record U.S. PrEP market share of more than 45% (Gilead company disclosure, Q4 2025 earnings call)
Employees (as of December 31, 2025) Approximately 17,000, down from approximately 17,600 at year-end 2024 (FY2025 Form 10-K)

Revenue by Product/Franchise (FY2025)

Total Revenue: $29.44B

Gilead Sciences FY2025 earnings release, twelve months ended December 31, 2025. HIV, Liver Disease, Oncology and Other are product-sales franchises; Veklury (COVID-19 antiviral) and Royalty/Contract/Other revenues are reported separately. Slices sum to $29,442M vs. the reported $29,443M total (rounding).

Total Revenue Growth

Gilead Sciences total revenues by fiscal year, FY2021-FY2025, as reported in each year's Q4/full-year earnings release. Revenue was roughly flat FY2021-FY2023 as declining Veklury/COVID-19 sales offset HIV franchise growth, then reaccelerated in FY2024-FY2025 on Biktarvy and Descovy growth.

Sources: Figures are from Gilead Sciences' Q4/Full-Year 2025 earnings release (reported February 10, 2026, filed as an SEC 8-K exhibit) and the FY2025 Form 10-K. Gilead reports product sales by franchise (HIV, Liver Disease, Oncology, Other) plus Veklury (COVID-19 antiviral) separately, and non-product 'Royalty, contract and other revenues'; these six lines sum to $29,442M against a reported total of $29,443M (a $1M rounding difference), noted in the pie subtitle. Gilead does not disclose operating income or margin by franchise/segment -- it operates and reports profitability as a single reportable segment -- so no operating-income pie is included; company-wide GAAP operating income and margin appear in the KPI table instead. The HIV/PrEP market-share figures are Gilead's own company-disclosed estimates (not an independent third party), given on the Q4 2025 earnings call by Chief Commercial Officer Johanna Mercier, and are presented as such.